News
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
1don MSN
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
Pharmaceutical Technology on MSN1d
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
16hon MSN
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback